Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Bamlanivimab/etesevimab  COVID-19 treatment studies for Bamlaniv../e..  C19 studies: Bamlaniv../e..  Bamlaniv../e..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies
VanBlargan et al., bioRxiv, doi:10.1101/2021.12.15.472828 (Preprint) (In Vitro)
VanBlargan et al., An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal.., bioRxiv, doi:10.1101/2021.12.15.472828 (Preprint) (In Vitro)
Dec 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
In vitro study (Vero-TMPRSS2 and Vero-hACE2-TMPRSS2) showing complete loss of inhibitory activity for B.1.1.529 omicron with LY-CoV555, LY-CoV016, REGN10933, REGN10987, and CT-P59, ~12-fold decrease for COV2-2196/COV2-2130, and minimal change for S309.
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, VanBlargan].
4 In Vitro studies support the efficacy of bamlanivimab/etesevimab [Liu (B), Sheward (B), VanBlargan (B), Zhou].
VanBlargan et al., 17 Dec 2021, preprint, 10 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperBamlaniv../e..All
Abstract: bioRxiv preprint doi: https://doi.org/10.1101/2021.12.15.472828; this version posted December 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by 2 several therapeutic monoclonal antibodies 3 4 Laura A. VanBlargan1, John M. Errico2, Peter J. Halfmann3, Seth J. Zost4,5, James E. Crowe 5 Jr.4,5,6, Lisa A. Purcell7, Yoshihiro Kawaoka3,8,9, Davide Corti10, Daved H. Fremont2,11,12, and 6 Michael S. Diamond1,2,11,13,14 7 8 1 Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA 9 2 Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, 10 USA 11 3 12 University of Wisconsin-Madison, Madison, WI, USA. 13 4 Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA 14 5 Department of Pediatrics Vanderbilt University Medical Center, Nashville, TN, USA 15 6 Department of Pathology, and Microbiology and Immunology, Vanderbilt University Medical Center, 16 Nashville, TN, USA 17 7 Vir Biotechnology, St Louis, MO, USA. 18 8 Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, 19 University of Tokyo, 108-8639 Tokyo, Japan. 20 9 21 Research Institute, Tokyo 162-8655, Japan. 22 10 Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. 23 11 Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO. 24 12 Department of Biochemistry & Molecular Biophysics, Washington University School of Medicine, St. 25 Louis, MO. 26 13 27 Washington University School of Medicine, Saint Louis, MO. 28 14 29 Saint Louis, MO. 30 Corresponding author: Michael S. Diamond, M.D., Ph.D., mdiamond@wustl.edu Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.12.15.472828; this version posted December 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 31 ABSTRACT 32 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the 33 global COVID-19 pandemic resulting in millions of deaths worldwide. Despite the 34 development and deployment of highly effective antibody and vaccine countermeasures, 35 rapidly-spreading SARS-CoV-2 variants with mutations at key antigenic sites in the spike 36 protein jeopardize their efficacy. Indeed, the recent emergence of the highly-transmissible 37 B.1.1.529 Omicron variant is especially concerning because of the number of mutations, 38 deletions, and insertions in the spike protein. Here, using a panel of anti-receptor binding 39 domain (RBD) monoclonal antibodies (mAbs) corresponding to those with emergency..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit